IDWeek 2026 Exhibitors
Oct 21–24, 2026 Washington, DC ~12k attendees Website
102 organizations exhibit at IDWeek 2026 — 52 diagnostics companies and suppliers, 34 drug and vaccine developers, 12 government bodies and non-profits and 4 hospitals and health systems. 45 of them also present on the scientific program, with 324 presentations between them. Most represented: Centers for Disease Control and Prevention, Pfizer and Gilead Sciences. As of Oct 16, 2026.
Topic
Top represented
Showing 1–30 of 102 organizations
| Organization | IDWeek 2026 Attendance |
|---|---|
Centers for Disease Control and Prevention Atlanta, GA | |
U.S. public health agency; its emerging and zoonotic infectious diseases center detects, tracks and responds to outbreaks and healthcare-associated infections. | Booth Exhibiting at Booth 311 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Talk Tue Oct 20 9:25am–10:15am CDC Core Elements for Outpatient Stewardship: An Updated Framework Antimicrobials, resistance and stewardship Talk Thu Oct 22 8:25am–8:50am Cyclospora 2026: What Have We Learned? Global and public health Session Thu Oct 22 10:30am–11:45am Connecting Across Perspectives: A Shared Path to Disease Elimination Global and public healthTransplant and immunocompromised hostsVaccines Talk Thu Oct 22 11:20am–11:45am Vaccines, Autonomy and Agency Global and public healthTransplant and immunocompromised hostsVaccines Talk Thu Oct 22 11:30am–11:45am Poster Thu Oct 22 12:15pm–1:30pm Candida lipolytica Pseudo-Outbreak Associated with Blood Culture Collection in an Acute Care Hospital Poster Thu Oct 22 12:15pm–1:30pm Demographic and Clinical Characteristics of Patients with Sporotrichosis in Seven Medical Centers, United States Poster Thu Oct 22 12:15pm–1:30pm Genomic insights into the absence of detectable carbapenemase genes in carbapenem-resistant Escherichia coli from the Antibiotic Resistance in Communities and Hospitals (ARCH) Study, India Poster Thu Oct 22 12:15pm–1:30pm Onsite availability of, clinical practices, and barriers related to respiratory virus vaccination reported by long-term care health care providers Poster Thu Oct 22 12:15pm–1:30pm Permitted But Not Chosen: Treatment Choice and Duration for Possible Congenital Syphilis – United States, 2018–2023 Talk Thu Oct 22 1:45pm–2:00pm 60-Day Mortality Among Adults Hospitalized with Laboratory-Confirmed Respiratory Syncytial Virus Infection Respiratory infections and COVID-19 Session Thu Oct 22 1:45pm–3:00pm Session Thu Oct 22 1:45pm–3:00pm From Global to Local: The New Face of Threats to U.S. Public Health Global and public health Talk Thu Oct 22 2:10pm–2:35pm Malaria in the United States: Epidemiology and Updated Treatment Guidance for Providers Global and public healthAntimicrobials, resistance and stewardship Talk Thu Oct 22 2:33pm–2:45pm Session Thu Oct 22 3:15pm–4:30pm Pediatric infectious diseases named lecture Global and public healthAntimicrobials, resistance and stewardship Talk Thu Oct 22 3:39pm–3:51pm Talk Thu Oct 22 3:51pm–4:03pm Measles Transmission in Schools – North and South Carolina, 2025–2026 Global and public health Talk Thu Oct 22 4:15pm–4:27pm Outbreak of Carbapenemase–Producing Salmonella Newport Infections Linked to Moringa Capsules Global and public healthAntimicrobials, resistance and stewardship Session Fri Oct 23 8:00am–9:00am Expanding the Diagnostic Toolkit for Viral Hepatitis and Managing Unique Infected Populations HIV, sexually transmitted infections and viral hepatitisDiagnostics and diagnostic stewardship Session Fri Oct 23 8:00am–9:00am Talk Fri Oct 23 8:30am–9:00am Identifying High-Priority Diagnostics and Implementation Considerations in Support of Viral Hepatitis Elimination in the United States HIV, sexually transmitted infections and viral hepatitisDiagnostics and diagnostic stewardship Talk Fri Oct 23 10:50am–11:10am Insights on Ebola from the CDC Global and public health Poster Fri Oct 23 12:15pm–1:30pm Antibiotic Use in a Cohort of U.S. Long-Term Care Facilities Using Electronic Health Record Data, 2022 Poster Fri Oct 23 12:15pm–1:30pm Causes of Death Among Adult People Living with HIV in Tajikistan: Findings from a National HIV Care Cohort, 2010–2023 Poster Fri Oct 23 12:15pm–1:30pm Changes in HIV Antiretroviral Prescribing Patterns During Pregnancies Covered by Public Insurance in the United States, 2010-2023 Poster Fri Oct 23 12:15pm–1:30pm Characteristics and clinical outcomes of immunocompromised adults hospitalized with RSV infection in a multistate surveillance network, RSV-NET, United States, 2022–2026 Poster Fri Oct 23 12:15pm–1:30pm Factors Associated with HIV Integrase Inhibitor Prescription During Pregnancies Covered by Public Insurance in the United States, 2018-2023 Poster Fri Oct 23 12:15pm–1:30pm Rural–Urban Differences in Daily Oral PrEP Prescriptions and Abandonment in the United States, 2022–2024: A National Observational Cohort Study Poster Fri Oct 23 12:15pm–1:30pm Survival After ART Initiation in Tajikistan Across ART Policy Eras: Evidence from a National HIV Cohort, 2010–2023 Poster Fri Oct 23 12:15pm–1:30pm U.S. Outpatient Antibiotic Prescribing, 2011-2024: Changes During Two Decades of Stewardship Session Fri Oct 23 1:45pm–3:00pm Emerging Infections From a One Health Lens Global and public health Talk Fri Oct 23 1:45pm–2:10pm Melioidosis in the Americas: An Evolving Situation Global and public health Session Fri Oct 23 1:45pm–3:00pm “HOT” Topics in Pediatric Infectious Diseases Transplant and immunocompromised hosts Talk Fri Oct 23 2:10pm–2:35pm New World Screwworm Global and public health Talk Fri Oct 23 3:30pm–3:45pm Influenza-associated encephalopathy among children with influenza-associated death – United States, 2025-2026 influenza season Respiratory infections and COVID-19 Talk Fri Oct 23 3:51pm–4:03pm Session Fri Oct 23 4:45pm–6:00pm Lecture in Vaccinology Vaccines Session Sat Oct 24 8:00am–9:00am Connecting Continents: Shared Challenges and Contrasting Customs in Peds ID Global and public health Session Sat Oct 24 8:00am–9:00am Public Health Departments Driving Statewide Antibiotic and Diagnostic Stewardship Global and public healthAntimicrobials, resistance and stewardship Session Sat Oct 24 10:30am–11:45am Enteric Vaccines: Celebrating the Past and Planning the Future Global and public healthVaccines Session Sat Oct 24 10:30am–11:45am Talk Sat Oct 24 10:30am–10:55am Polio Vaccines and Ending Polio Global and public healthVaccines Talk Sat Oct 24 10:42am–10:54am Parental Health Insurance and Use of HIV Prevention Services in Young Adults HIV, sexually transmitted infections and viral hepatitis Talk Sat Oct 24 10:54am–11:06am Trends in Drug Payments for HIV Preexposure Prophylaxis in the United States, 2019–2025: The Generic and Long-Acting Era HIV, sexually transmitted infections and viral hepatitis Poster Sat Oct 24 12:15pm–1:30pm Disease Severity of Human Metapneumovirus Compared with COVID-19, Influenza, and Respiratory Syncytial Virus Among Hospitalized Adults — IVY Network, September 1, 2022 – April 30, 2025 Poster Sat Oct 24 12:15pm–1:30pm Effectiveness of 2025–2026 seasonal influenza vaccines against U.S. pediatric influenza-associated emergency department and urgent care encounters — VISION Network, October 1, 2025–March 4, 2026 Poster Sat Oct 24 12:15pm–1:30pm Effectiveness of 2025–2026 seasonal influenza vaccines against influenza–associated hospitalizations among adults — VISION Network Poster Sat Oct 24 12:15pm–1:30pm Effectiveness of RSV Vaccines in Older Adults in the United States, VISION, 2023-2026 Poster Sat Oct 24 12:15pm–1:30pm Epidemiology and Trends of Invasive Non-toxigenic Corynebacterium diphtheriae in the United States, 2014–2024 Poster Sat Oct 24 12:15pm–1:30pm Incidence of RSV infections among participants in the CASCADIA Prospective Community Cohort Study, Oregon and Washington, United States, November 2023–March 2024 Poster Sat Oct 24 12:15pm–1:30pm Influenza Testing in Urgent Care, Emergency Department, and Inpatient Settings Among Children and Adults – VISION Network, 2023–24 and 2024–25 Seasons. Poster Sat Oct 24 12:15pm–1:30pm Population-Based Surveillance of Antifungal Susceptibility Among Uncommon Candida Species Causing Candidemia, United States, 2017–2025 Poster Sat Oct 24 12:15pm–1:30pm Post-licensure safety monitoring of 20-valent pneumococcal conjugate vaccine (PCV20) in children 2 – 24 months of age in the Vaccine Safety Datalink Poster Sat Oct 24 12:15pm–1:30pm Post-marketing Safety Surveillance of 21-valent Pneumococcal Conjugate Vaccine (PCV21) Among U.S. Adults in the Vaccine Adverse Event Reporting System (VAERS), during June 27, 2024 through December 31, 2025 Poster Sat Oct 24 12:15pm–1:30pm Prior Health Status as the Primary Predictor of Post-COVID Conditions: Evidence from a Bayesian Additive Regression Trees (BART) Analysis Poster Sat Oct 24 12:15pm–1:30pm RSV Immunization Effectiveness among Infants in their First RSV Season in the United States– VISION, October 2025-March 2026 Poster Sat Oct 24 12:15pm–1:30pm Recrudescence and Relapse of Melioidosis in the United States, 2008-2025 Poster Sat Oct 24 12:15pm–1:30pm Safety of live attenuated seasonal influenza vaccine (LAIV) in children aged 2 through 17 years in the Vaccine Adverse Events Reporting System (VAERS), 2018–2023 Poster Sat Oct 24 12:15pm–1:30pm Severity, Infectiousness, and Treatment of Macrolide-Resistant Bordetella pertussis: A Systematic Review Poster Sat Oct 24 12:15pm–1:30pm U.S. Physician Beliefs and Attitudes Towards an Anticipated Lyme Disease Vaccine Session Sat Oct 24 1:45pm–3:00pm Hot Topics in Pulmonary Fungal Infections Respiratory infections and COVID-19 Talk Sat Oct 24 2:10pm–2:35pm Endemic Fungi Causing Community-Acquired Pneumonia Respiratory infections and COVID-19 Session Sat Oct 24 3:15pm–4:30pm So Many Ways to Break an Immune System: Host Dysregulation, Modern Immunosuppressants and the Opportunistic Infections That Slip in Through the Cracks Transplant and immunocompromised hosts |
Pfizer New York, NY | |
Global pharmaceutical company whose infectious disease portfolio includes pneumococcal, RSV and COVID-19 vaccines and the COVID-19 antiviral Paxlovid. | Booth Exhibiting at Booth 1024, BS 6, BS 7 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Thu Oct 22 7:00am–8:00am Real-World Evidence on Adult Respiratory Vaccines and Select Acute and Post-Acute Outcomes Associated With Respiratory Infections VaccinesRespiratory infections and COVID-19 Industry Thu Oct 22 11:15am–12:00pm Helping to Protect Eligible Adult Patients Against Pneumococcal Disease Caused by Medically Important Serotypes VaccinesRespiratory infections and COVID-19 Poster Thu Oct 22 12:15pm–1:30pm Clostridioides difficile incidence among adults with underlying health conditions in the United States, 2018 – 2024 Poster Thu Oct 22 12:15pm–1:30pm Increasing National Burden of Clostridioides difficile Infection Cases, Hospitalizations, and Deaths in the United States, 2017-2023 Industry Thu Oct 22 1:15pm–2:00pm The Evolving COVID-19 Antiviral Landscape: Insights from Pfizer's Development Pipeline Antimicrobials, resistance and stewardshipRespiratory infections and COVID-19 Talk Thu Oct 22 3:51pm–4:03pm Talk Thu Oct 22 4:03pm–4:15pm Industry Fri Oct 23 10:15am–11:00am Help Protect Adults Who Are at Risk With a Respiratory Syncytial Virus (RSV) Vaccine VaccinesRespiratory infections and COVID-19 Industry Fri Oct 23 11:15am–12:00pm Sticking it to COVID-19: Updates on the Disease and a Vaccine Option from BioNTech and Pfizer VaccinesRespiratory infections and COVID-19 Poster Fri Oct 23 12:15pm–1:30pm Impact of Lyme Disease on Patient-Reported Outcomes in the United States: A Prospective Survey Study Talk Fri Oct 23 3:27pm–3:39pm Improved Virologic Control in Severely Immunocompromised (SIC) Adults with COVID-19 Receiving Extended Duration Paxlovid Therapy Antimicrobials, resistance and stewardshipTransplant and immunocompromised hosts Talk Fri Oct 23 4:15pm–4:27pm Industry Fri Oct 23 6:30pm–7:30pm COVID-19, an Evolving Disease - The ACE-2 Narrative Respiratory infections and COVID-19 Industry Sat Oct 24 10:30am–10:50am Talk Sat Oct 24 11:06am–11:18am Safety and Immunogenicity of LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Children 5–11 Years of Age VaccinesRespiratory infections and COVID-19 Talk Sat Oct 24 11:18am–11:30am Poster Sat Oct 24 12:15pm–1:30pm 13-valent pneumococcal conjugate vaccine: 3-year impact on risk of major adverse cardiovascular events among Medicare beneficiaries in the United States Poster Sat Oct 24 12:15pm–1:30pm 20-valent pneumococcal conjugate vaccine: Impact and effectiveness against all-cause outcomes among the general population of US older adults by age group, regardless of prior pneumococcal vaccine history Poster Sat Oct 24 12:15pm–1:30pm A Phase 3 Study to Investigate the Safety, Tolerability, and Immunogenicity of BNT162b2 RNA-based Variant-adapted Vaccine Candidate (LP.8.1) against SARS-CoV-2 in Participants 12 through 64 Years of Age Considered at Higher Risk of Severe COVID-19 and Participants ≥ 65 Years of Age Poster Sat Oct 24 12:15pm–1:30pm Acute COVID-19 Symptom Burden Among U.S. Adults During the 2025–2026 Respiratory Disease Season: Results from a Nationwide Study Poster Sat Oct 24 12:15pm–1:30pm Acute Symptom Burden of Influenza Infection Among US Adults During the 2025-2026 Respiratory Season: A Nationwide Prospective Study Poster Sat Oct 24 12:15pm–1:30pm Asthma and COPD Exacerbations Before and After the Emergence of SARS-CoV-2 in the United States Poster Sat Oct 24 12:15pm–1:30pm COVID-19 Symptom Burden and Comorbidity Profile among US Adults at High Risk for Severe COVID-19 Poster Sat Oct 24 12:15pm–1:30pm Comparison of Healthcare Resource Utilization and Costs of Respiratory Syncytial Virus Infection between Vaccinated and Unvaccinated US Medicare Beneficiaries Poster Sat Oct 24 12:15pm–1:30pm Cost Effectiveness of the Pfizer Pentavalent MenABCWY Vaccine Administered With an Extended Dosing Interval: Public Health and Economic Outcomes With a Novel Two-Dose Adolescent Meningococcal Vaccination Strategy Poster Sat Oct 24 12:15pm–1:30pm Crowded Fall Vaccination in Retail Pharmacy Setting among US Adults Aged 50 years and Older Poster Sat Oct 24 12:15pm–1:30pm Efficacy of Ibuzatrelvir on Sustained Overall Symptom Alleviation: Post-hoc Analysis from a Phase 2b Randomized Clinical Trial Poster Sat Oct 24 12:15pm–1:30pm Estimating the Incidence of RSV-Attributable Respiratory and Cardiorespiratory Hospitalizations among High-Risk Patients in Select High- and Middle-Income Countries Poster Sat Oct 24 12:15pm–1:30pm Impact of COVID-19 on Health-Related Quality of Life and Work Productivity Among US Adults in the 2025-2026 Respiratory Season: Results from a Nationwide Longitudinal Study Poster Sat Oct 24 12:15pm–1:30pm Inpatient Burden of COVID-19 Among Individuals with and without Chronic Kidney Disease in Japan Poster Sat Oct 24 12:15pm–1:30pm Long COVID in High-Risk Pediatric Subpopulations Poster Sat Oct 24 12:15pm–1:30pm Multisystem Incident Post-COVID Conditions in Individuals with Pre-existing Cardiometabolic Disease Poster Sat Oct 24 12:15pm–1:30pm Number Needed to Vaccinate for Pediatric Pneumococcal Conjugate Vaccines: How Dynamic Transmission Modeling Reshapes Comparative Estimates for PCV20 and PCV15 Poster Sat Oct 24 12:15pm–1:30pm Patient Characteristics Underlying COVID-19 Antiviral Prescribing decisions in Primary, Urgent, and Emergency Care Settings Poster Sat Oct 24 12:15pm–1:30pm Pneumococcal Conjugate Vaccine Series Completion Among Children with Medicaid Insurance in Selected States of the United States, 2021-2023 Poster Sat Oct 24 12:15pm–1:30pm Pregnancy and Infant Outcomes Following Exposure to PAXLOVID: Interim Results from A Post-Authorization Safety Study Poster Sat Oct 24 12:15pm–1:30pm Public Health Impact and Cost-Effectiveness of Revaccination with Bivalent Respiratory Syncytial Virus Prefusion F Vaccination Among Immunocompromised Adults in the United States Poster Sat Oct 24 12:15pm–1:30pm Public Health and Economic Impact of Complementary Infant Immunization Strategies against Respiratory Syncytial Virus (RSV) in Canada Given Shifting Seasonal Patterns Poster Sat Oct 24 12:15pm–1:30pm RSV Burden in Adults in Emerging Market Countries, a Systematic Review and Modelling Analysis Poster Sat Oct 24 12:15pm–1:30pm RSV Testing Rates by Comorbidities and Age Groups among Adults Hospitalized for Lower Respiratory Infections in the United States, September 2024 to April 2025 Poster Sat Oct 24 12:15pm–1:30pm RSV Testing Trends among Adults Hospitalized for Respiratory Infections in the United States, September 2019 to April 2025 Poster Sat Oct 24 12:15pm–1:30pm Real-world Effectiveness of Nirmatrelvir-Ritonavir in Reducing Severe COVID-19 Outcomes by Age Groups in Canada Poster Sat Oct 24 12:15pm–1:30pm Stability of Risk Condition-Associated Incidence Rate Ratios for Pediatric Infectious Disease Across Episode Gap Definitions Poster Sat Oct 24 12:15pm–1:30pm The Burden of Human Parainfluenza Virus (PIV) in Adults: A Systematic Literature Review and Meta-analysis Poster Sat Oct 24 12:15pm–1:30pm The Burden of Influenza Infection on Health-Related Quality of Life and Work Productivity Among US Adults During the 2025-2026 Respiratory Season: A Nationwide Prospective Study Poster Sat Oct 24 12:15pm–1:30pm Why Are Only a Minority of Eligible Patients Prescribed COVID-19 Antivirals? |
Gilead Sciences Foster City, CA | |
Biopharmaceutical company that has developed medicines for more than 30 years with the aim of a healthier world. | Booth Exhibiting at Booth 1301, BS 15, BS 23, BS 24 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Wed Oct 21 11:00am–12:30pm Advancing a Panviral Approach to HDV, HCV, HBV and HIV Prevention and Treatment: Lunch Symposium- food is provided by IDWeek HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship Talk Wed Oct 21 11:05am–12:30pm Industry Wed Oct 21 7:00pm–9:00pm Voice of the ART (ists): Dinner Symposium- food is provided by IDWeek HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship Industry Thu Oct 22 7:00am–8:00am Advances in HIV Prevention: The Future is Now - Breakfast Symposium- food is provided by IDWeek HIV, sexually transmitted infections and viral hepatitis Industry Thu Oct 22 12:15pm–1:00pm Paired With Intention: Explore the data behind a novel combination in appropriate virologically suppressed PWH HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship Industry Fri Oct 23 7:00am–8:30am Coffee, Croissants and Capsids, Oh My! - Breakfast Symposium: food is provided by IDWeek HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship Poster Fri Oct 23 12:15pm–1:30pm Association between Treatment Persistence and Healthcare Resource Utilization and Costs Among People with HIV Receiving Oral Antiretroviral Therapy Poster Fri Oct 23 12:15pm–1:30pm Changes in Pre‑Exposure Prophylaxis (PrEP) Cost Sharing and HIV Diagnoses Following United States Preventive Services Task Force (USPSTF) and Affordable Care Act (ACA) Coverage Milestones: An Interrupted Time Series Analysis Poster Fri Oct 23 12:15pm–1:30pm Community HERO Treatment Survey: Characterizing Treatment Journey for Older Persons With HIV Poster Fri Oct 23 12:15pm–1:30pm Descriptive Evaluation of a Medical Affairs–Led Educational Resource to Support Healthcare Providers in the Implementation of Lenacapavir for HIV PrEP Poster Fri Oct 23 12:15pm–1:30pm Evaluating the National- and State-Level Economic and Public Health Effect of Introduction of a Twice-Yearly Injectable PrEP Coupled With Minimal Overall PrEP Expansion in the General US Population and MSM Poster Fri Oct 23 12:15pm–1:30pm Incidence of resistance-associated mutations among people with HIV receiving bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based regimens Industry Fri Oct 23 12:15pm–1:00pm Learn About a PrEP Injectable Option HIV, sexually transmitted infections and viral hepatitis Poster Fri Oct 23 12:15pm–1:30pm Pharmacokinetic and clinical data supporting the lenacapavir (LEN) reloading strategy for bictegravir/lenacapavir (BIC/LEN) single-tablet regimen dosing in the ARTISTRY studies Poster Fri Oct 23 12:15pm–1:30pm Pre-Exposure Prophylaxis (PrEP) Uptake and Care in Locations of High HIV Incidence for Black Cisgender Women (CGW) in the US, 2024 Poster Fri Oct 23 12:15pm–1:30pm Routine HIV Screening to Prevention Services: Diversifying Linkage to HIV Prevention Services across 98 Emergency Departments, Community Health Centers, and High Impact Settings Talk Sat Oct 24 10:30am–10:42am Early Real-World Adoption Patterns of Long-Acting Lenacapavir for HIV PrEP in the United States (June 2025–March 2026) HIV, sexually transmitted infections and viral hepatitis Poster Sat Oct 24 12:15pm–1:30pm Resistance Analysis of Emergent Nsp12 Substitutions Observed in Immunocompromised COVID-19 Patients Treated with Remdesivir Poster Sat Oct 24 12:15pm–1:30pm Virology Analyses from the Obeldesivir Phase 2 Study in Nonhospitalized Adults with Acute Respiratory Syncytial Virus (RSV) Infection Talk Sat Oct 24 12:25pm–12:30pm Changes in Pre‑Exposure Prophylaxis (PrEP) Cost Sharing and HIV Diagnoses Following United States Preventive Services Task Force (USPSTF) and Affordable Care Act (ACA) Coverage Milestones: An Interrupted Time Series Analysis HIV, sexually transmitted infections and viral hepatitis Talk Sat Oct 24 12:30pm–12:35pm Routine HIV Screening to Prevention Services: Diversifying Linkage to HIV Prevention Services across 98 Emergency Departments, Community Health Centers, and High Impact Settings HIV, sexually transmitted infections and viral hepatitisDiagnostics and diagnostic stewardship |
Merck Rahway, NJ | |
Global biopharmaceutical company, called MSD outside the US and Canada, that develops medicines and vaccines for people and animals. | Booth Exhibiting at Booth 605, 705, BS 26, BS 27 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Poster Thu Oct 22 12:15pm–1:30pm Clesrovimab safety and exposure levels in infants under 2 kilograms: A subgroup analysis of the phase 3 SMART study Poster Thu Oct 22 12:15pm–1:30pm Clinical and Economic Burden of Infection Related to Carbapenem-resistant Pathogens in Taiwan Poster Thu Oct 22 12:15pm–1:30pm Impact of Antidrug Antibodies on the Pharmacokinetics, RSV Serum-Neutralizing Activity, and Safety of Clesrovimab in a Phase 3 Trial (SMART) Poster Thu Oct 22 12:15pm–1:30pm Impact of Clesrovimab on Commercially Available RSV Rapid Antigen Based Diagnostic Assays Poster Thu Oct 22 12:15pm–1:30pm RSV Coinfection With Community Respiratory Pathogens Following Administration of Clesrovimab in the Phase 3 SMART Trial Poster Thu Oct 22 12:15pm–1:30pm RSV Incidence Rates in RSV Season 2 of the Phase 3 SMART Trial of Clesrovimab: Impacts of Participant Population and RSV Circulation Talk Thu Oct 22 12:20pm–12:25pm RSV Incidence Rates in RSV Season 2 of the Phase 3 SMART Trial of Clesrovimab: Impacts of Participant Population and RSV Circulation Respiratory infections and COVID-19Vaccines Industry Fri Oct 23 7:00am–8:00am Help Protect Infants From RSV Lower Respiratory Tract Disease in Their First RSV Season Respiratory infections and COVID-19Vaccines Industry Fri Oct 23 8:00am–9:00am Recognizing and Addressing Risks of Shifting Epidemiology of Pneumococcal Disease in Adults 50+ VaccinesRespiratory infections and COVID-19 Industry Fri Oct 23 11:15am–12:00pm Exploring a Switch Regimen for Appropriate Adults Living With HIV-1 HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship Poster Fri Oct 23 12:15pm–1:30pm Exploring Preferences and Adherence & Persistence among Individuals Initiating PrEP in Portugal: the POSITIVE CARE Study Poster Fri Oct 23 12:15pm–1:30pm Exposure-Response Analysis of Islatravir 0.25 mg With Doravirine 100 mg Once Daily in Treatment-Naive and Virologically Suppressed People Living With HIV-1 at Week 48 Poster Fri Oct 23 12:15pm–1:30pm Potential Drug-Drug Interactions in People Living With HIV on Antiretroviral Therapy Stratified by Age and Sex Poster Fri Oct 23 12:15pm–1:30pm Switching to Islatravir + Ulonivirine Once Weekly Maintained HIV-1 Viral Suppression at Week 24 in the Presence of Baseline NNRTI Resistance-Associated Mutations and M184I/V in Proviral DNA Talk Sat Oct 24 11:30am–11:43am Phase 1 Study to Evaluate the Absorption, Metabolism, and Excretion of MK-8527, a Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults Without HIV HIV, sexually transmitted infections and viral hepatitis Poster Sat Oct 24 12:15pm–1:30pm A Comparative Analysis of HIV Transmission Model Structure with Matched Survey-Derived Contact-Rate Inputs: Policy Implications Under Economic and Resource Trade-offs Poster Sat Oct 24 12:15pm–1:30pm Anti Drug Antibody Responses to Clesrovimab Are Driven by Natural RSV Exposure Following Declining Protective Antibody Levels and Are Mitigated by Second-Season Dosing Poster Sat Oct 24 12:15pm–1:30pm Barriers to PrEP, HIV knowledge and perceived stigma among MSM and Heterosexual People Living with HIV in Portugal: The POSITIVE CARE Study Poster Sat Oct 24 12:15pm–1:30pm Comparisons of Population Effects of Pneumococcal Vaccination Programs in the United States and Canada — Considerations for Future Immunization Policy Poster Sat Oct 24 12:15pm–1:30pm Disease Severity and Serotype Distribution of PCV15-Type Non-Bacteremic Pneumococcal Pneumonia Among Hospitalized Adults in Taiwan Poster Sat Oct 24 12:15pm–1:30pm Population-Level Effects of Pneumococcal Conjugate Vaccines on Pneumococcal Disease in Europe: A Targeted Literature Review Poster Sat Oct 24 12:15pm–1:30pm Safety and Immunogenicity of V116, an Adult-specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults ≥50 Years of Age: Post-hoc Analysis of Phase 3 Data in the Overall and East Asian Populations Poster Sat Oct 24 12:15pm–1:30pm Social Determinants of Adult Vaccination in the United States (US): An Analysis of the National Health Interview Survey (NHIS) |
St. Jude Children's Research Hospital Memphis, TN | |
Pediatric research hospital for childhood cancer and other life-threatening diseases, whose infectious diseases department focuses on immunocompromised children and trains pediatric ID fellows. | Booth Exhibiting at Booth 1027 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Talk Tue Oct 20 10:40am–12:00pm Panel Discussion: Stewardship in Immunocompromised Patients Antimicrobials, resistance and stewardshipTransplant and immunocompromised hosts Session Wed Oct 21 8:00am–8:10am Session Wed Oct 21 10:00am–10:15am Session Wed Oct 21 12:10pm–12:15pm Session Wed Oct 21 1:30pm–3:15pm Mano-a-Mano HIV, sexually transmitted infections and viral hepatitis Poster Thu Oct 22 12:15pm–1:30pm Antibiotic Salvage Treatment of Gram-negative Catheter-related Bloodstream Infections in Children with Cancer Poster Thu Oct 22 12:15pm–1:30pm Extreme Pharmacokinetic Variability for Broad Spectrum Beta-Lactam Antibiotics in Children and Adolescents with Leukemia Poster Thu Oct 22 12:15pm–1:30pm Importance of Multi-pathogen Interactions in the Etiology and Pathogenesis of Pediatric Community Acquired Pneumonia Poster Thu Oct 22 12:15pm–1:30pm Integrated Host and Pathogen Profiling Validates Clinical Challenges in the Diagnosis and Management of Pediatric Lower Respiratory Infections Poster Thu Oct 22 12:15pm–1:30pm Pneumococcal Density and Respiratory Syncytial Virus (RSV) Interactions in Children with RSV Infection Poster Thu Oct 22 12:15pm–1:30pm Risk of Recurrent, Cefepime-Resistant, Gram-Negative Infections During Febrile Neutropenia in Children with Cancer Talk Thu Oct 22 12:40pm–12:45pm Pneumococcal Density and Respiratory Syncytial Virus (RSV) Interactions in Children with RSV Infection Respiratory infections and COVID-19 Session Fri Oct 23 8:00am–9:00am Talk Fri Oct 23 10:30am–10:45am Short Course Compared to Standard Antibiotic Courses for Treatment of Uncomplicated Gram-negative Bacteremia in Pediatric HCT Recipients Antimicrobials, resistance and stewardshipTransplant and immunocompromised hosts Poster Fri Oct 23 12:15pm–1:30pm A Prospective Observational Study of Adjunctive Glycopeptide Prophylaxis in Children and Adolescents with Acute Myeloid Leukemia Receiving Myelosuppressive Therapy Poster Fri Oct 23 12:15pm–1:30pm Leveraging Imputed Gene Expression to Discover and Validate Genomic Risk Factors for Sepsis During Pediatric Leukemia Therapy Poster Fri Oct 23 12:15pm–1:30pm Severity-Associated Immune Dysregulation During Gram-Negative Sepsis in Pediatric Leukemia Differs by Infection Phase Talk Fri Oct 23 3:15pm–3:30pm Respiratory syncytial virus (RSV) genomic diversity influences mucosal innate immune responses and disease severity in young children Respiratory infections and COVID-19 Talk Fri Oct 23 3:45pm–4:00pm Host Transcriptomics Identify Undetected Bacterial Co-Infections in Children Classified with Viral Community-Acquired Pneumonia Diagnostics and diagnostic stewardshipRespiratory infections and COVID-19 Talk Fri Oct 23 4:00pm–4:15pm Talk Sat Oct 24 10:42am–10:54am [18F]-Fluoromannitol PET for Specific Detection of Invasive Bacterial Infection: Preclinical Models to First-in-Human Study Diagnostics and diagnostic stewardship Poster Sat Oct 24 12:15pm–1:30pm Cardiac Magnetic Resonance Imaging in the Immediate Post-Sepsis Period in Children With Cancer: A Prospective Observational Study |
GSK Philadelphia, PA | |
Biopharma company that prevents and treats disease with vaccines and with specialty and general medicines. | Booth Exhibiting at Booth 1105, 1117, BS 2 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Thu Oct 22 12:15pm–1:00pm Focusing on Complicated UTI: An Oral Option for Appropriate Patients Antimicrobials, resistance and stewardship Poster Thu Oct 22 12:15pm–1:30pm Human Simulated Dosing Regimens of Tebipenem Were Effective in a Rat Pyelonephritis Model against 16 Enterobacterales Poster Thu Oct 22 12:15pm–1:30pm Pharmacokinetic-Pharmacodynamic and Exposure-Response Assessment of Oral Tebipenem in Patients with Complicated Urinary Tract Infections Including Acute Pyelonephritis Poster Thu Oct 22 12:15pm–1:30pm Refined Pharmacokinetic/Pharmacodynamic (PK/PD) Targets to Support Oral Tebipenem (TBP) Treatment for Complicated Urinary Tract Infections (cUTI) Talk Thu Oct 22 2:30pm–2:45pm Estimating the Burden of Influenza in the Absence of Vaccination in the US Respiratory infections and COVID-19Vaccines Talk Thu Oct 22 3:45pm–4:00pm Talk Thu Oct 22 3:51pm–4:03pm Adjuvanted RSVPreF3 vaccine effectiveness against RSV-related hospitalization among US adults aged ≥60 years: Results from the CLEAR-VE RSV study over two RSV seasons VaccinesRespiratory infections and COVID-19 Industry Fri Oct 23 10:30am–10:50am Targeting HBsAg loss in HIV/HBV Co-Infection HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship Industry Fri Oct 23 11:15am–12:00pm How PO Can You Go? IV to Oral Transition of Antimicrobials for Complicated UTIs Antimicrobials, resistance and stewardship Industry Fri Oct 23 12:15pm–1:00pm Hepatitis B Continuum of Care: Closing Gaps in Prevention to Treatment HIV, sexually transmitted infections and viral hepatitis Poster Sat Oct 24 12:15pm–1:30pm Boosting Uptake, Expanding Eligibility: Quantifying the Population and Equity Benefits of a Flu-Like COVID-19 Vaccination Strategy, a UK Example Poster Sat Oct 24 12:15pm–1:30pm Economic and Humanistic Burden of COVID‑19 in the US: Targeted Evidence Synthesis from the Post-Pandemic Era Poster Sat Oct 24 12:15pm–1:30pm Exploring Respiratory Syncytial Virus Vaccination Conversations Between Primary Care Providers and Their Adult Patients in the United States Poster Sat Oct 24 12:15pm–1:30pm Impact of Antibiotic Treatment Duration on Treatment-Related Adverse Events in Female Patients with Uncomplicated Urinary Tract Infections in the United States Poster Sat Oct 24 12:15pm–1:30pm Modeled Public Health Impact of Infant Meningococcal Serogroup B Vaccination Across United States Insurance Populations Poster Sat Oct 24 12:15pm–1:30pm Patient Reported Pain, Quality of Life, and Productivity Burden Following Herpes Zoster among United States Adults Aged 50–64 Years Poster Sat Oct 24 12:15pm–1:30pm Real-World Effectiveness of Ibrexafungerp in Patients with Vulvovaginal Candidiasis Poster Sat Oct 24 12:15pm–1:30pm Serotype-Specific Immune Response Elicited by Pneumococcal Conjugate Vaccines: a Systematic Literature Review Poster Sat Oct 24 12:15pm–1:30pm Variability in RSV Vaccination Uptake Across US Health Care Organizations and Across Primary Care Providers within US Health Care Organizations Poster Sat Oct 24 12:15pm–1:30pm hMPV Burden of Disease among Older Adults in High-Income Countries: a Systematic Literature Review |
Moderna Cambridge, MA | |
mRNA medicine company whose platform yields vaccines and therapies across infectious disease, cancer immunotherapy, rare disease and autoimmunity. | Booth Exhibiting at Booth 1424, BS 13, BS 14 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Talk Thu Oct 22 2:45pm–3:00pm Talk Sat Oct 24 10:54am–11:06am Efficacy and Immunogenicity of an mRNA-Based Seasonal Influenza Vaccine in Older Adults: A Subanalysis of the Phase 3 FLUENT Trial VaccinesRespiratory infections and COVID-19 Poster Sat Oct 24 12:15pm–1:30pm Characterizing the Symptoms of Infectious Mononucleosis in an Upper Midwest Population, USA Poster Sat Oct 24 12:15pm–1:30pm Comorbidities of Adults with Medically Attended Influenza and COVID-19 Infection in the United States Poster Sat Oct 24 12:15pm–1:30pm Describing Care Setting Patterns for Norovirus Gastroenteritis in US Adults 2019–2024: A MarketScan Database Analysis Poster Sat Oct 24 12:15pm–1:30pm Estimated Impact of Increasing RSV Vaccination Coverage on Burden Among Older Adults in the Veterans Health Administration Poster Sat Oct 24 12:15pm–1:30pm Incidence of Acute Gastroenteritis in a Community Cohort in Peru Poster Sat Oct 24 12:15pm–1:30pm Incidence of Acute Respiratory Infections in a Community Cohort in Peru Poster Sat Oct 24 12:15pm–1:30pm Influenza and COVID-19 Vaccine Coverage Rates among Adults With and Without High-Risk Comorbidities Poster Sat Oct 24 12:15pm–1:30pm Post-Authorization Active Surveillance Safety Study Using Secondary Data to Monitor Real World Safety of mRESVIA® for Respiratory Syncytial Virus in the United States: Interim Descriptive Analyses Poster Sat Oct 24 12:15pm–1:30pm Post-Marketing Safety of an 2024-2025 mRNA-1273 COVID vaccine (mRNA-1273.712): A U.S. Claims-Based Active Surveillance Study (Optum’s de-identified Clinformatics® Data Mart Database and Humana Medicare Advantage Database) Poster Sat Oct 24 12:15pm–1:30pm Projected Public Health Impact of mRNA-1345 Revaccination Strategies in the ACIP-Recommended US Adult Population Poster Sat Oct 24 12:15pm–1:30pm Public Health and Economic Impact of mRNA-1345 Vaccination on RSV Burden in US Adults Using First-Season Real-World Effectiveness Poster Sat Oct 24 12:15pm–1:30pm Real-World Co-administration Patterns of mRNA-1283 COVID-19 Vaccine with Influenza and Other Vaccines in the United States Poster Sat Oct 24 12:15pm–1:30pm Severity of Test-Confirmed HMPV, Influenza, RSV, and SARS-CoV-2 Acute Respiratory Hospitalizations in Adults, 2022-2025 |
Shionogi Osaka, Japan | |
Japanese pharmaceutical company focused on infectious diseases, whose U.S. subsidiary develops and sells anti-infective medicines. | Booth Exhibiting at Booth 815, BS 10, BS 3, BS 4 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Poster Thu Oct 22 12:15pm–1:30pm Activity of Cefiderocol Against Carbapenem-Resistant Pseudomonas aeruginosa Encountered In Each of the Different United States Census Bureau Divisions Poster Thu Oct 22 12:15pm–1:30pm Activity of Cefiderocol against Metallo-Beta-Lactamase Carrying Pseudomonas aeruginosa of the SENTRY Antimicrobial Surveillance Program (2020 – 2024) Poster Thu Oct 22 12:15pm–1:30pm Activity of cefiderocol against carbapenem nonsusceptible Gram-negative isolates from skin and soft tissue infections in US and European medical centers collected as part of the SENTRY antimicrobial surveillance program (2020-2024) Poster Thu Oct 22 12:15pm–1:30pm Bactericidal Activity of Cefiderocol/Xeruborbactam in a Murine Urinary Tract Infection Model Poster Thu Oct 22 12:15pm–1:30pm Clinical Outcomes After Cefiderocol Therapy for Pseudomonas spp. Infections: Results from a Systematic Literature Review Poster Thu Oct 22 12:15pm–1:30pm Outcomes of Cefiderocol Treatment in US Patients with Respiratory Tract Infections: Subgroup Analysis of the PROVE Observational Study Poster Thu Oct 22 12:15pm–1:30pm Systematic Literature Review of the Clinical Outcomes Associated with Cefiderocol Therapy for Stenotrophomonas maltophilia Infections Talk Fri Oct 23 12:25pm–12:30pm Cefiderocol Activity Across Highly Resistant Pseudomonas aeruginosa Ventilator-Associated Pneumonia Isolates: A Global Surveillance Study of SENTRY 2020-2024 Antimicrobials, resistance and stewardshipRespiratory infections and COVID-19 Talk Fri Oct 23 3:15pm–3:27pm Early Pre-Symptomatic Treatment with Ensitrelvir Among PCR-Positive, SARS‑CoV‑2–Exposed and Infected Household Contacts: SCORPIO‑PEP Subpopulation Analysis Antimicrobials, resistance and stewardshipRespiratory infections and COVID-19 Poster Sat Oct 24 12:15pm–1:30pm Brain Microstructural Disorganization as a Potential Mechanism of post-COVID-19 Condition and the Onset-suppressive Effects of Ensitrelvir Revealed by Advanced Diffusion MRI–based Translational Research Poster Sat Oct 24 12:15pm–1:30pm Cefiderocol Activity Across Highly Resistant Pseudomonas aeruginosa Ventilator-Associated Pneumonia Isolates: A Global Surveillance Study of SENTRY 2020-2024 Poster Sat Oct 24 12:15pm–1:30pm Ensitrelvir Suppresses Fatigue-like Symptoms Derived from SARS-CoV-2 Infection in Hamsters Poster Sat Oct 24 12:15pm–1:30pm Impact of Acute COVID-19 on Underlying Chronic Conditions: Systematic Literature Review Poster Sat Oct 24 12:15pm–1:30pm Reduction of Infectious SARS-CoV-2 and Viral Titer with Ensitrelvir: A Pooled Analysis of SCORPIO-SR and SCORPIO-HR Trials |
ViiV Healthcare London, UK | |
Pharmaceutical company focused solely on HIV, researching and delivering medicines for people living with HIV or seeking to prevent it. | Booth Exhibiting at Booth 905, BS 1 A, BS 1 B, BS 1 C Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Session Thu Oct 22 2:00pm–2:30pm IDBugCrawl: ViiV Session Progress Made Personal: Bringing Long-Acting HIV Treatment and Prevention to Life for the Patients We See Every Day HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship Poster Fri Oct 23 12:15pm–1:30pm Dolutegravir + Lamivudine in People with HIV-1 Who Are Naive to Antiretroviral Therapy with Baseline Viral Load ≥500,000 c/mL: Systematic Literature Review and Meta-Analysis of Real-World Evidence Poster Fri Oct 23 12:15pm–1:30pm Early Expectations of Cabotegravir Every 4 Month Injections for HIV Pre-Exposure Prophylaxis among Individuals Using Cabotegravir Every 2 Month Injectable Poster Fri Oct 23 12:15pm–1:30pm Human Immunodeficiency Virus (HIV) Testing and Evidence of HIV among Real-World Long-Acting Pre-Exposure Prophylaxis (PrEP) Users in a United States Claims Database: Updated Results from the PrEPFACTS Study Poster Fri Oct 23 12:15pm–1:30pm Immune Recovery Continues to Improve over 5 years with Fostemsavir Despite Emergent gp120 Substitutions Poster Fri Oct 23 12:15pm–1:30pm Modelling the Future Epidemiological and Economic Burden of HIV in the United States: Substantial New Diagnoses and Additional Costs Projected Under Current Care Patterns Poster Fri Oct 23 12:15pm–1:30pm Modelling the impact of scale-up of long-acting injectables for HIV prevention and treatment in the United States (US) Poster Fri Oct 23 12:15pm–1:30pm Racial and Ethnic Differences in Long Acting Cabotegravir for HIV-1 Pre-Exposure Prophylaxis Experience in a US Real-World Cross‑Sectional Study: Results from the CAPTIVATE Study Poster Fri Oct 23 12:15pm–1:30pm Real-world Persistence of Long Acting Cabotegravir for HIV Pre-Exposure Prophylaxis in the United States: Results from the PrEPFACTS Study Using Healthcare Administrative Claims Data Poster Fri Oct 23 12:15pm–1:30pm The Evolution of Integrase Strand Transfer Inhibitors: VH-184, a 3rd-Generation Inhibitor with an Enhanced Resistance Profile Poster Fri Oct 23 12:15pm–1:30pm User Experience Concepts Assessed Among People in the United States Using Long-Acting Injectable Cabotegravir for PrEP in Real-World Care: Results from the CAPTIVATE Study Industry Fri Oct 23 1:15pm–2:00pm |
Veterans Health Administration Washington, DC | |
Health care arm of the US Department of Veterans Affairs, serving enrolled veterans through a national network of medical centers and clinics. | Booth Exhibiting at Booth 1044 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Poster Thu Oct 22 12:15pm–1:30pm Information-theoretic approaches to identify infectious outbreaks with surprising features Poster Fri Oct 23 12:15pm–1:30pm Multicenter Evaluation of Appropriateness Criteria for Empiric Antipseudomonal Therapy in Hospitalized Veterans Poster Fri Oct 23 12:15pm–1:30pm The Geography and Impact of Coccidioidomycosis: Analysis of the VA Vector Borne Environmental and Zoonotic Diseases (VBEZD) Dashboard, 2000 – 2025 Poster Fri Oct 23 12:15pm–1:30pm Vector Database Similarity Matching for Avian Influenza Biosurveillance in Patient Notes Poster Sat Oct 24 12:15pm–1:30pm Measles Infection Surveillance and Vaccinations, Veterans Health Administration, 2016 to 2025 Session Sat Oct 24 1:45pm–3:00pm STD Advances: GC & Beyond HIV, sexually transmitted infections and viral hepatitis |
Diasorin Stillwater, MN | |
Immunodiagnostics and molecular diagnostics company offering specialty assays on integrated platforms that simplify laboratory testing. | Booth Exhibiting at Booth 1525 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Thu Oct 22 11:15am–12:00pm One Size Fits None: Finding the Right Molecular GI Testing Strategy for Your Lab Diagnostics and diagnostic stewardship Poster Thu Oct 22 12:15pm–1:30pm Analytical Agreement Between LIAISON MeMed BV and MeMed Key Host-Response Assays in Patients with Suspected Lower Respiratory Tract Infection Poster Thu Oct 22 12:15pm–1:30pm Bridging the U.S. Diagnostic Gap: A Multi- Assay Comparison of an Automated Measles IgM Assay Poster Thu Oct 22 12:15pm–1:30pm Clinical Performance of a CLIA-Waived, Point-of-Care Assay for the Detection of Influenza A, Influenza B, RSV and SARS-CoV-2 Viruses Poster Thu Oct 22 12:15pm–1:30pm Rapid and Sensitive Molecular Point-of-Care System for Detection of Group A Strep in Throat Swabs Industry Thu Oct 22 1:15pm–2:00pm Yeast, Parasites, and Panels: Unique Case Studies in Syndromic Molecular Testing Diagnostics and diagnostic stewardship Industry Fri Oct 23 1:15pm–2:00pm A yeast of burden: managing Candida auris in healthcare Infection prevention and healthcare epidemiology Industry Sat Oct 24 8:00am–8:25am Diasorin Prevalence Software for LIAISON PLEX®: A Prevalence Analytics Platform for Flexible Syndromic Testing Diagnostics and diagnostic stewardship |
Labcorp Burlington, NC | |
Global laboratory services company offering diagnostic testing and drug development lab support, running hundreds of millions of patient tests each year. | Booth Exhibiting at Booth 917 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Poster Thu Oct 22 12:15pm–1:30pm AMRWGS: An Evidence-Tiered Genomic AMR Reporting Framework for Large-Scale WGS Assessment of Resistance Detection and Blind Spots Industry Fri Oct 23 10:15am–11:00am Real-World Insights From a Large Commercial Laboratory: Diagnostic Gaps and Testing Trends Across Viral Hepatitis, Syphilis and Measles Diagnostics and diagnostic stewardshipHIV, sexually transmitted infections and viral hepatitis Talk Fri Oct 23 1:45pm–2:00pm Syphilis testing outcomes among people with HIV: a national reference laboratory retrospective study (2018–2025) HIV, sexually transmitted infections and viral hepatitisDiagnostics and diagnostic stewardship Poster Sat Oct 24 12:15pm–1:30pm Characteristics of Samples Received for HDV Quantitative RNA Testing and Development of an HDV Sequencing Assay. Poster Sat Oct 24 12:15pm–1:30pm Development and Validation of a Multiplex Influenza A Subtyping Assay (InfAST) for Currently Circulating Strains of Influenza A H1, H3 and H5 Poster Sat Oct 24 12:15pm–1:30pm Measles Testing in 2026: Continued Rise in Volume and Positivity Across the United States Poster Sat Oct 24 12:15pm–1:30pm Traditional or Reverse? Real-World Performance of Syphilis Screening Algorithms in a Reference Laboratory (2018–2025) |
AstraZeneca Wilmington, DE | |
Global biopharmaceutical company developing and selling prescription medicines in oncology, rare diseases, respiratory, cardiovascular and other areas. | Booth Exhibiting at Booth 1611, BS 11, BS 12 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Session Fri Oct 23 12:00pm–12:55pm Poster Fri Oct 23 12:15pm–1:30pm Outcomes of Respiratory Syncytial Virus Infection Among Adults with Immunocompromising Conditions: A Systematic Literature Review Poster Sat Oct 24 12:15pm–1:30pm Incidence of Hospitalisation Due to Human Metapneumovirus (hMPV) Among Adults with Underlying Comorbidities in Spain Poster Sat Oct 24 12:15pm–1:30pm Severe Acute Respiratory Infections in Hospitalized Adults Requiring Respiratory Support in Europe: A Subgroup Analysis of the id.DRIVE Study 2024–2025 Poster Sat Oct 24 12:15pm–1:30pm Structure-based Optimization of a Bivalent Vaccine Against Respiratory Syncytial Virus and Human Metapneumovirus |
bioMérieux Salt Lake City, UT | |
In vitro diagnostics company whose systems, reagents and software identify the cause of infections, with work on antibiotic resistance and sepsis. | Booth Exhibiting at Booth 825 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Poster Thu Oct 22 12:15pm–1:30pm Accuracy of ETEST® Gradient MIC Strip for Fastidious Bacteria Poster Thu Oct 22 12:15pm–1:30pm Comparative Evaluation of Cefepime-Zidebactam (Zaynich®) MIC Testing with Gradient Strip (ETEST®) and CLSI Broth Microdilution Methods Poster Thu Oct 22 12:15pm–1:30pm Prevalence and Co-occurrence of Bacterial Vaginosis, Vulvovaginal Candidiasis and Trichomoniasis in Peru, India, and the United States- Results from an Investigational-Use-Only Molecular Test for Vaginitis Talk Thu Oct 22 4:03pm–4:15pm Real-Time Multiplex Gastrointestinal PCR Surveillance Detects and Localizes the 2026 Cyclospora cayetanensis Outbreak Ahead of National Notifiable Disease Reporting Diagnostics and diagnostic stewardshipGlobal and public health |
Innoviva Specialty Therapeutics Waltham, MA | |
Innoviva subsidiary developing and selling critical care and infectious disease medicines, including an antibiotic for Acinetobacter infections and a septic shock vasopressor. | Booth Exhibiting at Booth 515 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Wed Oct 21 11:00am–12:00pm The Evolving Management of S. aureus Bacteremia: 2026 Updates and Emerging Evidence Antimicrobials, resistance and stewardship Poster Thu Oct 22 12:15pm–1:30pm Pediatric Dose Selection of Ceftobiprole for Staphylococcus aureus Bacteremia, Including Right‑Sided Infective Endocarditis Using Model-Based Approaches Poster Sat Oct 24 12:15pm–1:30pm Extrapolation of Adult Efficacy and Safety to Support Pediatric Use of Ceftobiprole for Acute Bacterial Skin and Skin Structure Infections Talk Sat Oct 24 2:15pm–2:30pm Zoliflodacin Maintains High Rates of Microbiologic Eradication of Urogenital Neisseria gonorrhoeae in Patients Co-infected with Chlamydia trachomatis Antimicrobials, resistance and stewardshipHIV, sexually transmitted infections and viral hepatitis |
Sanofi Paris, France | |
Global healthcare company developing medicines and vaccines, with teams in some 100 countries. | Booth Exhibiting at Booth 1225, BS 21, BS 22, BS 28 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Thu Oct 22 12:15pm–1:00pm Invasive Meningococcal Disease Across the Lifespan: Changing Epidemiology and Emerging Risk Populations VaccinesGlobal and public health Industry Fri Oct 23 12:15pm–1:00pm The Great Debate: Which Communication Strategy Works Best for Infant RSV Immunization? VaccinesRespiratory infections and COVID-19 Poster Sat Oct 24 12:15pm–1:30pm Exploring Superiority of MenACWY-TT Vaccine Compared to MenACWY-CRM Vaccine in Adolescents – a Post-hoc Analysis. Poster Sat Oct 24 12:15pm–1:30pm Real-World Strains, Real-World Protection: Meningococcal ACWY Conjugate Vaccine (MenACWY-TT) Demonstrates Robust Immunogenicity Against Circulating Hypervirulent Serogroup Y ST-1466 |
AIDS Healthcare Foundation Los Angeles, CA | |
Nonprofit providing HIV/AIDS medical care and advocacy to millions of people in about 50 countries, funded partly by its pharmacies and thrift stores. | Booth Exhibiting at Booth 1443 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Talk Fri Oct 23 11:05am–11:45am Making Long-acting Work in the Face of Questionable Resistance: To LEN or Not to LEN? Antimicrobials, resistance and stewardship Talk Fri Oct 23 11:18am–11:30am Serologic Response Following Doxycycline Versus Benzathine Penicillin G for Syphilis Treatment: A Propensity Score-Matched Analysis HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship Talk Fri Oct 23 2:21pm–2:33pm High Suppression and Rare Virologic Failure with Long-Acting Cabotegravir + Rilpivirine: Real World Evidence Over Five Years from the OPERA Cohort HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship |
Bavarian Nordic Durham, NC | |
Danish vaccine maker whose products include the Jynneos mpox and smallpox vaccine and a chikungunya virus-like particle vaccine. | Booth Exhibiting at Booth 1706 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Talk Thu Oct 22 11:00am–11:15am Talk Sat Oct 24 11:30am–11:42am Poster Sat Oct 24 12:15pm–1:30pm Chikungunya Virus Virus-like Particle Vaccine Elicits Cross-Neutralization Across CHIKV Lineages and Against Other Alphaviruses After Single Dose |
Healix Sugar Land, TX | |
Runs a network of 300+ outpatient infusion centers and an accredited pharmacy that supplies injectable and infused medicines. | Booth Exhibiting at Booth 1243 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Poster Thu Oct 22 12:15pm–1:30pm Five-Year Real-World Trends in Outpatient Anti-Infective Therapy Across U.S. Physician Office Infusion Centers Session Fri Oct 23 12:15pm–12:45pm Rapid-Fire Poster Session: Old Foes, New Strategies Antimicrobials, resistance and stewardship Poster Sat Oct 24 12:15pm–1:30pm Infection Rate Reduction in Primary Immunodeficiency Patients Following Initiation of High-Titer Immunoglobulin: A Real-World Analysis |
National Foundation for Infectious Diseases Bethesda, MD | |
Nonprofit that educates the public and health professionals about infectious diseases and vaccination across the lifespan. | Booth Exhibiting at Booth 319 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Session Fri Oct 23 1:45pm–3:00pm Revenge of the Syph: Syphilis Diagnostics, Prevention and Treatment HIV, sexually transmitted infections and viral hepatitis Session Fri Oct 23 1:45pm–3:00pm Session Fri Oct 23 3:15pm–4:30pm |
Vaxcyte San Carlos, CA | |
Vaccine company developing broader-coverage pneumococcal conjugate vaccines, led by VAX-31, a 31-valent candidate in Phase 3 trials. | Booth Exhibiting at Booth BS 16, BS 25 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Thu Oct 22 1:30pm–1:50pm Poster Sat Oct 24 12:15pm–1:30pm Design and Rationale of the Phase 3 OPUS-1, OPUS-2, and OPUS-3 Trials Evaluating a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults Poster Sat Oct 24 12:15pm–1:30pm Projected Public Health Impacts of PCV20, PCV21, and VAX-31, a 31-Valent Investigational Pneumococcal Conjugate Vaccine, in US Adults |
Bruker Billerica, MA | |
Instrument maker whose MALDI Biotyper identifies microbes from culture in minutes, plus infrared strain typing and ELITechGroup molecular diagnostics. | Booth Exhibiting at Booth 1732 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Fri Oct 23 1:30pm–1:50pm Closing the Blood Culture Gap with Rapid Phenotypic Antimicrobial Susceptibility Testing Diagnostics and diagnostic stewardshipAntimicrobials, resistance and stewardship Talk Sat Oct 24 11:15am–11:30am AI-Powered MALDI-TOF Platform for Rapid Antimicrobial Susceptibility Testing: Clinical Impact in Taiwan and Multi-Center Validation in the US Diagnostics and diagnostic stewardshipAntimicrobials, resistance and stewardship |
Offers Delve Detect, a metagenomic sequencing test that identifies bacteria, viruses, fungi and parasites in cerebrospinal fluid and plasma. | Booth Exhibiting at Booth 411 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Poster Thu Oct 22 12:15pm–1:30pm Clinical Characteristics of Neuroinvasive Arbovirus Infections Detected by Metagenomic Next-Generation Sequencing Poster Sat Oct 24 12:15pm–1:30pm Neurotropic Astrovirus VA Strain Detected by CSF Metagenomic Sequencing in Immunocompromised Hosts: A Case Series |
F2G Manchester, United Kingdom | |
Biotech developing olorofim, an oral antifungal from a new class, the orotomides, for invasive aspergillosis and other hard-to-treat mould infections. | Booth Exhibiting at Booth 1340 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Talk Thu Oct 22 10:42am–10:54am Olorofim versus AmBisome®-Based Standard of Care (SOC) for Treatment of Invasive Aspergillosis (IA) in Patients for Whom a Mold-Active Azole Antifungal (MAA) is Inappropriate or Ineffective (OASIS): A Phase 3, Randomized, Controlled, Adjudicator-Blinded Non-Inferiority (NI) Trial (NCT05101187) Antimicrobials, resistance and stewardship Poster Sat Oct 24 12:15pm–1:30pm Health-Related Quality of Life in Patients with Invasive Fungal Infections with Limited or No Treatment Options: An Analysis of the Phase 2b Olorofim Trial Data |
Pattern Bioscience Austin, TX | |
Developing a single-cell microbiology system to deliver identification, quantification and susceptibility results directly from specimens in about six hours, starting with pneumonia. | Booth Exhibiting at Booth 414 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Poster Thu Oct 22 12:15pm–1:30pm From stream to susceptibility: a pilot evaluation of direct-from-urine microorganism identification and phenotypic antimicrobial susceptibility testing Poster Thu Oct 22 12:15pm–1:30pm Hours, Not Days: Multi-center Evaluation of a Direct-from-Specimen Rapid Phenotypic ID, Semi-Quantification, and AST Test for Pneumonia |
Q-linea Uppsala, Sweden | |
Developer of ASTar, a fully automated system that reports rapid antimicrobial susceptibility results directly from positive blood cultures in about six hours. | Booth Exhibiting at Booth 1804 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Poster Thu Oct 22 12:15pm–1:30pm A Pooled Performance and Adjudication Analysis of ASTar® Rapid Antimicrobial Susceptibility Testing System from Gram-negative Blood Cultures Poster Thu Oct 22 12:15pm–1:30pm A workflow for Direct from Whole Blood Antimicrobial Susceptibility Testing (AST) using ASTar, a commercially available platform for rapid AST |
deepull Barcelona, Spain | |
Developing UllCORE, a one-hour PCR system that tests whole blood directly for the pathogens behind most sepsis cases. | Booth Exhibiting at Booth 1628 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Fri Oct 23 11:15am–12:00pm Direct From Whole Blood: Opportunities and Challenges in Rapid Detection of Pathogens and Antimicrobial Resistance Genes Diagnostics and diagnostic stewardshipAntimicrobials, resistance and stewardship |
Acurx Pharmaceuticals Staten Island, NY | |
Clinical-stage company developing a new class of antibiotics against bacteria that health agencies rank as priority pathogens. | Booth Exhibiting at Booth 620 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Thu Oct 22 10:30am–10:50am Novel Antibiotic for Both the Treatment and the Reduction of Recurrence of C. difficile Infection Antimicrobials, resistance and stewardship Industry Sat Oct 24 11:00am–11:20am Novel Antibiotic for Both the Treatment and the Reduction of Recurrence of C. difficile Infection Antimicrobials, resistance and stewardship |
Meitheal Pharmaceuticals Chicago, IL | |
Chicago company, founded 2017, that develops and sells generic injectable medicines, including anti-infectives, and has added fertility, biologic and branded products. | Booth Exhibiting at Booth 1342 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Thu Oct 22 11:15am–11:35am CONTEPO® (IV fosfomycin): Exploring unmet needs and clinical evidence Antimicrobials, resistance and stewardship Poster Sat Oct 24 12:15pm–1:30pm Timing, Severity, and Duration of Hypokalemia in Adults with Complicated Urinary Tract Infection Treated with Intravenous Fosfomycin (Contepo): Post Hoc Analysis of the ZEUS Trial |
National Jewish Health Denver, CO | |
Denver respiratory hospital and research center whose Advanced Diagnostic Laboratories offer specialized mycobacterial and immunology testing. | Booth Exhibiting at Booth 1828 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Session Thu Oct 22 8:00am–9:00am Return of the MAC: Management of Pulmonary NTMs Respiratory infections and COVID-19Antimicrobials, resistance and stewardship Talk Thu Oct 22 8:30am–9:00am Long-Term Medical Management of Pulmonary NTMs: MAC and M. abscessus? Respiratory infections and COVID-19Antimicrobials, resistance and stewardship |
Instantly find 20 buyers from IDWeek 2026 exhibitors
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse IDWeek 2026 by
Topic
- Antimicrobials, resistance and stewardship 420
- Vaccines 122
- Diagnostics and diagnostic stewardship 247
- HIV, sexually transmitted infections and viral hepatitis 256
- Infection prevention and healthcare epidemiology 292
- Transplant and immunocompromised hosts 173
- Respiratory infections and COVID-19 163
- Global and public health 211
Exhibit hall
- Exhibitors 102
Everyone
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction